AdhamJurdiMD

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Assistant Professor of Medicine

Dr. Jurdi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Adham Jurdi is an oncologist in Austin, TX, practicing with Austin Cancer Center. He previously worked with SUNY Upstate Medical University and Syracuse VAMC. He has been in practice since 2013. He subspecializes in Gastrointestinal and Thoracic malignancies.

East Tennessee State University/Quillen College of MedicineFellowship, Medical Oncology, 2011 - 2013
East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 2008 - 2011
Beirut Arab University Faculty of MedicineClass of 2006

PubMed

19 citations
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Yara L Verschoor, Joris van de Haar, José G van den Berg, Johanna W van Sandick, Liudmila L Kodach
Nature Medicine. 2024-02-01
20 citations
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani
JCO Precision Oncology. 2022-12-01
1 citations
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, Vasily N Aushev, Abdullah Esmail
The Oncologist. 2024-10-03

New Signateratm MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
New Signatera™ MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US TrialMarch 21st, 2022
Join now to see all